Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: BIA 28-6156 in Parkinson's Disease With GBA1 Variant
NCT05819359Phase 2Active, not recruiting
- Sponsor
- BIAL
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of pariceract in Parkinson's disease (PD), sponsored by BIAL. Started Mar 2023; status: active, not recruiting.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05819359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819359.